The Institute of Clinical and Economic on Thursday revealed its preliminary list of possible assessment candidates for 2019 as it continues to consider “new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public.”
ICER previously announced its February 2019 meeting will look at Novartis’ canakinumab for treating atherosclerosis, and will in March review AVXS-101 from Novartis and AveXis and Biogen’s nusinersen for treating spinal muscular atrophy.
Below are some of the topics under consideration for 2019, according to a press release:
- AR101 (Aimmune Therapeutics): peanut allergy;
- Diroximel fumarate (Biogen/Alkermes): relapsing multiple sclerosis;
- Brolucizumab (Novartis): wet age-related macular degeneration;
- Buprenorphine/Samidorphan (Alkermes): major depressive disorder; and
- Esketamine (Johnson & Johnson): major depressive disorder.
To read the full press release and to see ICER’s preliminary list, click here.
